Evidence map›Paper›PMID 32875001›Full record

ArticleOpen forum infectious diseases2020

Minimizing Time to Optimal Antimicrobial Therapy for Enterobacteriaceae Bloodstream Infections: A Retrospective, Hypothetical Application of Predictive Scoring Tools vs Rapid Diagnostics Tests.

Laura N Cwengros, Ryan P Mynatt, Tristan T Timbrook, Robert Mitchell, Hossein Salimnia, Paul Lephart, Jason M Pogue

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Exploring the intersection of racism, antimicrobial resistance, and vaccine equity.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022
    Article
  5. Observational
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Laura N CwengrosDepartment of Pharmacy Services, CJW Medical Center, Richmond, Virginia, USA.
Ryan P MynattDepartment of Pharmacy Services, University of Kentucky Healthcare, Lexington, Kentucky, USA.
Tristan T TimbrookBioFire Diagnostics, Salt Lake City, Utah, USA.
Robert MitchellMicrobiology Division, Detroit Medical Center University Laboratories, Detroit, Michigan, USA.
Hossein SalimniaMicrobiology Division, Detroit Medical Center University Laboratories, Detroit, Michigan, USA.
Paul LephartClinical Microbiology Laboratory, University of Michigan, Ann Arbor, Michigan, USA.
Jason M PogueDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
Detroit Medical Center · USUniversity of Michigan–Ann Arbor · USBioFire Diagnostics (United States) · USFraunhofer USA · USUniversity of Kentucky HealthCare · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBloodstream infections (BSIs) due to ceftriaxone (CRO)-resistant Enterobacteriaceae are associated with delays in time to appropriate therapy and worse outcomes compared with infections due to susceptible isolates. However, treating all at-risk patients with empiric carbapenem therapy risks overexposure. Strategies are needed to appropriately balance these competing interests. The purpose of this study was to compare 4 methods for achieving this balance.

methodsThis was a retrospective hypothetical observational study of patients at the Detroit Medical Center with monomicrobial BSIs due to

resultsFour hundred fifty-one Enterobacteriaceae BSIs were included, 73 (16%) of which were CRO-resistant. Verigene accurately predicted ceftriaxone susceptibility for 97% of isolates, compared with 70%-81% using the scoring tools (

conclusionsVerigene significantly outperformed published ESBL scoring tools for identifying CRO-resistant Enterobacteriaceae BSI. Institutions should validate scoring tools before implementation. Stewardship programs should consider adoption of rapid diagnostic tests to optimize early therapy.

Indexed as

ESBLrapid diagnosticstoolVerigene

Identifiers

PMID32875001
PMCPMC7452369
OpenAlexW3038393669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.